Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis was written by Cao, Shengtian;Yang, Xinye;Zhang, Zheng;Wu, Junwen;Chi, Bo;Chen, Hong;Yu, Jianghong;Feng, Shanshan;Xu, Yulin;Li, Jing;Zhang, Yingjun;Wang, Xiaojun;Wang, Yan. And the article was included in European Journal of Medicinal Chemistry in 2022.SDS of cas: 51834-97-0 This article mentions the following:
Synthesis and characterization of compound HEC96719 I a novel tricyclic FXR agonist based on a prior high-affinity nonsteroidal mol. GW4064 was reported. HEC96719 I exhibited excellent potency superior to GW4064 and obeticholic acid in in vitro and in vivo assays of FXR activation. It also showed higher FXR selectivity and more favorable tissue distribution dominantly in liver and intestine. Preclin. data on pharmacokinetic properties, efficacy, and safety profiles overall indicate that HEC96719 I was a promising drug candidate for NASH treatment. In the experiment, the researchers used many compounds, for example, 5-Hydroxy-2-methoxylpyridine (cas: 51834-97-0SDS of cas: 51834-97-0).
5-Hydroxy-2-methoxylpyridine (cas: 51834-97-0) belongs to pyridine derivatives. The pyridine ring occurs in many important compounds, including agrochemicals, pharmaceuticals, and vitamins. Pyridine groups exist in countless molecules, and their applications include catalysis, drug design, molecular recognition, and natural product synthesis.SDS of cas: 51834-97-0